A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid.

@article{Amagai2017ARD,
  title={A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid.},
  author={Masayuki Amagai and Shigaku Ikeda and Takashi Hashimoto and Masato Mizuashi and Akihiro Fujisawa and Hironobu Ihn and Yasushi Matsuzaki and Mikio Ohtsuka and Hiroshi Fujiwara and Junichi Furuta and Osamu Tago and Jun Yamagami and Akiko Tanikawa and Hisashi Uhara and Akimichi Morita and Gen Nakanishi and Mamori Tani and Y Aoyama and Eiichi Makino and Masahiko Muto and Motomu Manabe and Takayuki Konno and Satoru Murata and Seiichi Izaki and Hideaki Watanabe and Yukie Yamaguchi and Setsuko Matsukura and Mariko Seishima and Koji Habe and Yuichi Yoshida and Sakae Kaneko and Hajime Shindo and Kimiko Nakajima and Takuro Kanekura and Kenzo Takahashi and Yasuo Kitajima and Koji Hashimoto},
  journal={Journal of dermatological science},
  year={2017},
  volume={85 2},
  pages={77-84}
}
BACKGROUND Patients with steroid-resistant bullous pemphigoid (BP) require an appropriate treatment option. OBJECTIVE A multicenter, randomized, placebo-controlled, double-blind trial was conducted to investigate the therapeutic effect of high-dose intravenous immunoglobulin (IVIG; 400mg/kg/day for 5days) in BP patients who showed no symptomatic improvement with prednisolone (≥0.4mg/kg/day) administered. METHODS We evaluated the efficacy using the disease activity score on day15 (DAS15) as… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…